Avelumab Produces Durable Responses in Metastatic Merkel Cell Carcinoma

June 22, 2016

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

The phase II JAVELIN Merkel 200 trial found that the anti–PD-L1 agent avelumab produced durable responses in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9508).

In this video, Howard L. Kaufman, MD, of the Rutgers Cancer Institute of New Jersey, discusses these results.